NOVA Medical School, iNOVA4Health, CEDOC-Chronic Diseases Research Center, Edifício CEDOC II, Universidade NOVA de Lisboa, Rua Câmara Pestana no. 6, lab 3.16, 1150-082, Lisboa, Portugal.
Department of Internal Medicine, Hospital da Luz Lisboa, Avenida Lusíada, 100, 1500-650, Lisboa, Portugal.
Sci Rep. 2021 Apr 27;11(1):9036. doi: 10.1038/s41598-021-88393-3.
Sulfotransferase enzymes (SULT) catalyse sulfoconjugation of drugs, as well as endogenous mediators, gut microbiota metabolites and environmental xenobiotics. To address the limited evidence on sulfonation activity from clinical research, we developed a clinical metabolic phenotyping method using paracetamol as a probe substrate. Our aim was to estimate sulfonation capability of phenolic compounds and study its intraindividual variability in man. A total of 36 healthy adult volunteers (12 men, 12 women and 12 women on oral contraceptives) received paracetamol in a 1 g-tablet formulation on three separate occasions. Paracetamol and its metabolites were measured in plasma and spot urine samples using liquid chromatography-high resolution mass spectrometry. A metabolic ratio (Paracetamol Sulfonation Index-PSI) was used to estimate phenol SULT activity. PSI showed low intraindividual variability, with a good correlation between values in plasma and spot urine samples. Urinary PSI was independent of factors not related to SULT activity, such as urine pH or eGFR. Gender and oral contraceptive intake had no impact on PSI. Our SULT phenotyping method is a simple non-invasive procedure requiring urine spot samples, using the safe and convenient drug paracetamol as a probe substrate, and with low intraindividual coefficient of variation. Although it will not give us mechanistic information, it will provide us an empirical measure of an individual's sulfonator status. To the best of our knowledge, our method provides the first standardised in vivo empirical measure of an individual's phenol sulfonation capability and of its intraindividual variability. EUDRA-CT 2016-001395-29, NCT03182595 June 9, 2017.
磺基转移酶(SULT)催化药物、内源性介质、肠道微生物群代谢物和环境外源化学物质的磺酰化共轭反应。为了解决临床研究中关于磺化活性的有限证据,我们开发了一种使用对乙酰氨基酚作为探针底物的临床代谢表型方法。我们的目的是估计酚类化合物的磺化能力,并研究其在人体内的个体内变异性。共有 36 名健康成年志愿者(12 名男性、12 名女性和 12 名口服避孕药女性)分别在三次服用 1 克片剂形式的对乙酰氨基酚。使用液相色谱-高分辨率质谱法在血浆和尿样中测定对乙酰氨基酚及其代谢物。使用代谢比值(对乙酰氨基酚磺化指数-PSI)来估计酚类 SULT 活性。PSI 显示个体内变异性低,血浆和尿样中值之间具有良好的相关性。尿 PSI 与与 SULT 活性无关的因素无关,如尿 pH 值或 eGFR。性别和口服避孕药的摄入对 PSI 没有影响。我们的 SULT 表型方法是一种简单的非侵入性程序,需要尿样斑点,使用安全方便的药物对乙酰氨基酚作为探针底物,个体内变异系数低。尽管它不会提供机制信息,但它将为我们提供个体磺化剂状态的经验衡量标准。据我们所知,我们的方法提供了第一个标准化的个体酚类磺化能力及其个体内变异性的体内经验衡量标准。EUDRA-CT 2016-001395-29,NCT03182595 2017 年 6 月 9 日。